A.69 EPC Extent of protection

(1)

The extent of the protection conferred by a European patent or a European patent application shall be determined by the claims. Nevertheless, the description and drawings shall be used to interpret the claims.

(2)

For the period up to grant of the European patent, the extent of the protection conferred by the European patent application shall be determined by the claims contained in the application as published. However, the European patent as granted or as amended in opposition, limitation or revocation proceedings shall determine retroactively the protection conferred by the application, in so far as such protection is not thereby extended.

Amended by the Act revising the European Patent Convention of 29.11.2000.

The Protocol on the Interpretation of Article 69 EPC is an integral part of the Convention pursuant to Article 164, paragraph 1.

See decisions of the Enlarged Board of Appeal G 2/88, G 6/88 (Annex I).

Source: http://www.epo.org/law-practice/legal-texts/html/epc/2016/e/ar69.html

Date retrieved: 17 May 2021

80 references found.

Click X to load a reference inside the current page, click on the title to open in a new page.

EPC Articles

X Chapter III Effects of the European patent and the European patent application

X A.2 EPC European patent

X A.93 EPC Publication of the European patent application

X A.164 EPC Implementing Regulations and Protocols

EPO Guidelines - B Search

X GL B III 3.1 Basis for the search

EPO Guidelines - D Opposition and Limitation/Revocation Procedures

X GL D X 4.3 Scope of the examination

EPO Guidelines - E General Procedural Matters

X GL E XIII 2 Scope of the technical opinion

EPO Guidelines - F The European Patent Application

X GL F IV 1 General

X GL F IV 4.2 Interpretation

X GL F IV 4.12 Product-by-process claim

EPO Guidelines - H Amendments and Corrections

X GL H IV 3.1 Basic principles

X GL H IV 3.2 Protection conferred by the patent as granted

X GL H IV 3.4 Assessment of impermissible extension of the protection conferred

EPO PCT GL - F (not assigned)

X GL-PCT FOREWORD 3.1 Annex I: EPC-PCT concordance table

Offical Journal of the EPO

X OJ EPO SE 4/2020, p99 - ANNEX 1

X OJ EPO SE 4/2020, p23 - II. PATENT APPLICATION AND AMENDMENTS

X OJ EPO 2020, A87 - Decision of the Enlarged Board of Appeal of 16 July 2019 - G 2/19

X OJ EPO SE 3/2018, p2 - BOARDS OF APPEAL AND ENLARGED BOARD OF APPEAL CASE LAW 2017

X OJ EPO 2018, A70 - Decision of the Enlarged Board of Appeal dated 18 December 2017 – G 1/16

X OJ EPO SE 6/2017, p79 - E. Claims

X OJ EPO SE 6/2017, p46 - C. Inventive step

X OJ EPO SE 4/2017, p2 - BOARD OF APPEAL AND ENLARGED BOARD OF APPEAL CASE LAW 2015/2016

Case Law Book: I Patentability

X CLR I D 9.8.3 Broad claims

Case Law Book: II Conditions to be met by an Application

X CLR II A 1.1 Purpose of claims under Article 84 EPC

X CLR II A 5.3 Bringing the description into line with amended claims

X CLR II A 6.3.1 General principles

X CLR II A 6.3.2 Relevance of Article 69 EPC

X CLR II A 6.3.4 Reading additional features and limitations into the claims

X CLR II E 1.3.9 Claim interpretation when assessing compliance with Article 123(2) EPC

X CLR II E 2.3.1 ‍‍Article 123(3) EPC and Article 69 EPC

X CLR II E 2.3.3 General claim interpretation

X CLR II E 2.4.5 Deletion of a drawing

X CLR II E 2.4.13 Replacement by aliud

X CLR II F 5.2 Different subject-matter and scope of protection; overlapping subject-matter

Case Law Book: III Amendments

X CLR III H Interpretation of the EPC

X CLR III W 1 Guidelines not binding on boards

Case Law Book: IV Divisional Applications

X CLR IV C 5.1.8 Amendments intended to remedy a lack of clarity

Case Law of the Enlarged Board

X G 0002/88 (Friction reducing additive) of 11.12.1989

X G 0006/88 (Plant growth regulating agent/BAYER) of 11.12.1989

X G 0002/12 () of 25.3.2015

X G 0002/13 () of 25.3.2015

X G 0003/14 () of 24.3.2015

X G 0001/16 (Disclaimer III) of 18.12.2017

General Case Law

X T 0601/06 (Rating plugs) of 5.5.2009

X T 1208/06 () of 3.7.2008

X T 1808/06 () of 14.2.2008

X T 0418/07 (Human anti-TNFalpha antibodies/ABBOTT) of 4.5.2011

X T 2049/07 () of 8.9.2009

X T 0235/08 () of 8.4.2009

X T 0547/08 () of 10.3.2011

X T 1172/08 (Method for determining T-cell epitopes/GENENCOR) of 7.10.2011

X T 1798/08 () of 21.8.2012

X T 1870/08 () of 13.3.2012

X T 0162/09 (Virtuelles Papierdokument/ANSWERS) of 13.9.2012

X T 0195/09 (Scale inhibiting polymers/UNILEVER) of 8.10.2010

X T 0299/09 () of 8.6.2011

X T 0494/09 (Solution de facteur VIII sÃ©curisÃ©e viralement/LABORATOIRE FRANÃAIS) of 28.9.2011

X T 1570/09 (Alpha-ketoglutaric acid and pharmaceutically acceptable salts thereof … of 16.5.2014

X T 1736/09 () of 30.1.2014

X T 1871/09 () of 24.11.2015

X T 2259/09 () of 7.6.2013

X T 2284/09 () of 23.1.2013

X T 0287/10 (Surface treatment of paper/CIBA) of 15.5.2012

X T 2392/10 () of 12.11.2014

X T 1047/11 () of 8.3.2016

X T 1896/11 () of 25.11.2016

X T 2563/11 (Doppelpatentierung) of 5.9.2017

X T 2623/11 () of 15.3.2016

X T 0442/12 () of 12.4.2016

X T 0792/12 () of 14.9.2016

X T 1646/12 () of 26.6.2015

X T 1994/12 () of 19.4.2016

X T 0008/13 () of 10.12.2013

X T 1296/13 () of 15.12.2016

X T 1578/13 () of 27.11.2017

X T 0145/14 (MotorprÃ¼fstand/AVL) of 12.1.2017

X T 1817/14 (Expert system/SCHINDLER) of 4.7.2017

X T 1477/15 () of 23.2.2017

X T 2196/15 () of 26.6.2017

X T 0736/16 () of 26.4.2017